In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies

This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed or refractory malignant hematological tumors. It is an early exploratory clinical study of the safety, tolerability and initial efficacy in the treatment of relapsed or refractory malignant hematological tumors.

Trial Details

NCT ID
NCT07239323
Phase
PHASE1
Sponsor
Chongqing Precision Biotech Co., Ltd
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Invivo CAR-T
Locations (sample)
  • Kunming, Yunnan, China|25.03889,102.71833

Key Eligibility Criteria

  • Age ≥ 18 years old, gender unrestricted;
  • Confirmed diagnosis of relapsed/refractory malignant hematological tumors, including B-ALL, B-cell lymphoma and multiple myeloma;
  • ECOG performance status score 0-2, with an expected survival period of ≥ 3 months;
  • Blood routine test results during the screening period meet the following criteria:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →